nmdp logo

About Us

Your partner from patient diagnosis to treatment and recover

The cell therapy landscape is rapidly evolving, and so too is our partnership with you.

At NMDP℠, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy.

Discover how we work together with you throughout the treatment journey: advocating tirelessly to remove barriers to consultation and treatment, connecting patients to the optimal cell therapy and driving research to expand treatment options for all patients.

Together we will

Like the cell therapy industry, our partnership with you is rapidly evolving. Together we discover. Together we innovate. Together we will advance the future of care.

Our strategic pillars of action

Our vision is to create a world where every patient can receive their life-saving cell therapy. Our strategic pillars of action to get us there is to accelerate progress, serve as a world-class partner and expand access.

Accelerate progress

We seek to advance the cell therapy ecosystem to provide cures so all patients can thrive. A major contributor to this goal is our involvement in transformative research.

A global leader in research

As the leader in transformative research and outcomes analysis through the Center for International Blood and Marrow Transplant Research (CIBMTR), we design and support prospective and retrospective studies on emerging therapies, identify trends and provide tools to help you:

  • Make optimal cell source selections
  • Inform treatment strategies
  • Improve outcomes

With data from our world-renowned outcomes database, we establish and update evidence-based standards of care and clinical guidelines. Along with transplant outcomes, our outcomes database includes data for all commercially available manufactured cell therapy products.

With continual focus on improving outcomes, strategic initiatives are underway to use CIBMTR data to develop outcome prediction tools that recommend mismatched donors, haploidentical donors, cord blood, or cell and gene therapy products based on likely outcomes.

Serve as a world-class partner

We seek to deliver best in class experiences and service as the essential partner in cell therapy. Our goal is to provide every patient with the cell therapy they need, regardless of cell source. NMDP has the unique ability to source and transport cells globally using our proven, expansive supply chain network.

Our 30+ years of experience in logistics and supply chain management enables us to successfully navigate disruptions, from natural disasters to geopolitical events to a worldwide pandemic.

Unrelated donor and cord blood transplants

Despite varying registry requirements, we provide a standardized, consistent experience for searching and ordering from the global network.

We’re continually investing in increasing NMDP diversity, donor engagement and donor availability to expand treatment access for patients. We utilize data and research to support the search and graft source selection process for unrelated donors and cord blood units.

Through clinical trials, like 15-MMUD and ACCESS, we aim to establish a new role for mismatched unrelated donor transplants to expand access to transplants for diverse patients.

Related donor transplants

We can facilitate your patient’s haploidentical or fully matched related donor collection through Related Donor Services, helping to remove logistical and financial barriers to treatment. When we facilitate your patient’s related donor collection, your patient and U.S.-based donor both receive the full support and benefits we provide when we facilitate a transplant with an unrelated donor.

Emerging cell and gene therapies

Through NMDP BioTherapies℠, we partner with cell and gene therapy developers to empower the discovery, development and delivery of next-generation therapies, bridging the gap between pharmaceutical companies and providers.

We are also tracking outcomes data for leading pharmaceutical companies for therapies like CAR-T through the CIBMTR, providing insights about how the drugs work and which patients are best positioned to benefit from them.

CBIMTR research

Expand access

We continue to remove the barriers to equitable access to life-saving cell therapies by providing advocacy and resources.

Influencing health policy and driving coverage and reimbursement improvements

We collaborate with providers, payers and government officials to influence policy changes that improve access to care. For example, through the tireless work of our team, other industry leaders and volunteers from across the country, the Patient Access to Cellular Therapy (PACT) Act, also known as Section 108, was signed into law. The PACT Act improves Medicare transplant reimbursement. We’ve also worked to expand Medicare coverage to include sickle cell disease, myelofibrosis and multiple myeloma through national clinical studies facilitated by the CIBMTR.

Additionally, we teamed with other organizations and advocates on legislation passed into law that requires Medicaid to cover routine costs of care when a patient enrolls in a clinical trial for cancer and other severely debilitating conditions, like sickle cell disease.

Clearing pathways for more patients to receive cellular therapy

Through programs like HLA Today, we work with community hematologists/oncologists to drive early referrals to transplantcenters and improve patient outcomes. Additionally, we develop consultation timing guidelines in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)

Breaking down barriers to ensure Lisa received HCT

Download the case example to learn how HLA Today, Related Donor Services, and Patient Financial Assistance played key roles in a patient’s HCT journey from referral through post-transplant care.

Breaking down barriers for patients, caregivers and donors

Not every barrier in a patient’s road to treatment and recovery is related to their physical health. Sometimes it’s a patient’s psychosocial circumstances or financial health—like high out-of-pocket costs for lodging for the patient and caregiver before, during and after transplant.

We break down non-medical barriers patients, caregivers and donors face to ensure all patients receive the life-saving treatment they need.

Our dedicated NMDP Foundation® team raises funds that enable us to:

  • Add new potential donors to the NMDP Registry®
  • Conduct research to save more lives
  • Provide millions of dollars in financial assistance for patients, donors and caregivers for expenses before, during, and after transplant

For patients and caregivers, we offer confidential support, including one-on-one guidance, a patient-friendly searchable clinical trials database, educational resources and more.

We’ve also developed programs to engage registry members while they wait and improve availability when they’re called to donate.

More than 2300 patients received financial assistance in 2021

Resources, continued education and training for your team

Open book icon

Online Resource Library

Get no-cost educational resources for patients, caregivers and clinicians.

Computer monitor icon

Transplant Center Education & Events

Find webinars and other education to help you support your patients.

Check mark icon


Access the latest info on new initiatives, case studies and service enhancements.